This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of renal pelvis
C3_RENAL_PELVIS
renal pelvis carcinoma: A carcinoma arising in the renal pelvis. The majority of renal pelvis carcinomas are transitional cell and less frequently squamous cell carcinomas.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
208 |
4. Check minimum number of eventsNone |
208 |
5. Include endpointsNone |
208 |
6. Filter based on genotype QC (FinnGen only) |
203 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of renal pelvis
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of renal pelvis, including Hilmo
- Malignant neoplasm of urinary organs
- Solid cancers, helper endpoint
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 203 | 54 | 149 |
| Unadjusted period prevalence (%) | 0.06 | 0.02 | 0.07 |
| Median age at first event (years) | 72.40 | 71.83 | 72.60 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 208
- Matched controls
- 2080
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
255.2
189
*
8120/3-C65.9
ICD-O-3
Transitional cell carcinoma, NOS, of renal pelvis
+∞
212.8
166
*
UKC02
NOMESCO Finland
Cystoscopy
37.2
144.3
171
230
R31
ICD-10 Finland
Unspecified haematuria
17.2
100.1
126
171
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
61.1
89.1
51
11
H02AB02
ATC
dexamethasone; systemic
51.9
76.1
45
11
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
+∞
75.8
68
*
130
Kela drug reimbursment
Malignant tumour
+∞
74.6
67
*
KAC21
NOMESCO Finland
Percutaneous endoscopic nephroureterectomy
+∞
67.4
61
*
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
65.1
59
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
62.7
57
*
Z51.5
ICD-10 Finland
Palliative care
18.3
62.0
55
40
A03FA01
ATC
metoclopramide; systemic, rectal
9.3
49.0
74
116
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
47.8
44
*
KCD02
NOMESCO Finland
Transurethral resection of bladder
169.1
40.4
41
*
JN4AD
NOMESCO Finland
Body CT examination
10.4
38.9
49
60
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
413.1
36.1
35
*
UKA02
NOMESCO Finland
Retrograde ureteronephroscopy
+∞
35.4
33
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
35.4
33
*
B01AB10
ATC
tinzaparin; parenteral
8.6
33.4
49
72
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
52.9
33.2
39
9
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
12.5
32.2
34
32
UKB02
NOMESCO Finland
Retrograde ureteroscopy
187.9
31.6
32
*
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
174.2
29.5
30
*
XX3DW
NOMESCO Finland
Time consuming IT work
10.9
27.8
32
34
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
26.6
25
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
26.6
25
*
C66
ICD-10 Finland
Malignant neoplasm of ureter
+∞
26.6
25
*
N02AA05
ATC
oxycodone; systemic
5.2
26.3
72
193
JN4BD
NOMESCO Finland
Extensive body CT
8.8
25.4
35
47
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
282.5
25.3
25
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
24.5
24.9
35
17
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
23.4
22
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
257.2
23.1
23
*
B02AA02
ATC
tranexamic acid; systemic
6.6
22.3
40
72
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.4
21.6
51
119
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
85.5
21.1
23
*
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
122.4
21.0
22
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
18.0
17
*
A04AA01
ATC
ondansetron; systemic, rectal
21.6
17.4
25
13
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
69.3
17.0
19
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.5
16.1
34
71
8000/3-C65.9
ICD-O-3
Neoplasm, malignant of renal pelvis
+∞
15.8
15
*
L03AA02
ATC
filgrastim; parenteral
+∞
15.8
15
*
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
15.8
15
*
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
+∞
15.8
15
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
15.8
15
*
WZC00
NOMESCO Finland
Treatment plan or consultation
3.5
15.2
71
269
7126
FHL
Nephroureterectomy
+∞
13.7
13
*
KC1GB
NOMESCO Finland
Cystography with X-ray
+∞
13.7
13
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
+∞
13.7
13
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
13.7
13
*
ZX136
NOMESCO Finland
Intravesicalis
+∞
13.7
13
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
13.7
13
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
149.3
13.6
14
*
TPH07
NOMESCO Finland
Cathetrisation of artery
3.8
13.5
48
151
B01AB05
ATC
enoxaparin; parenteral
3.1
13.5
83
368
U06
ICPC
Haematuria
12.8
13.2
23
20
JN4CD
NOMESCO Finland
Very extensive body CT
26.3
12.7
17
7
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
12.6
12
*
116
Kela drug reimbursment
Prostate cancer
+∞
12.6
12
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.2
12.5
64
253
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
11.6
11
*
8130/3-C65.9
ICD-O-3
Papillary urothelial carcinoma of renal pelvis
+∞
11.6
11
*
1891C
ICD-9 Finland
Malignant neoplasm of kidney and other and unspecified urinary organs, Renal pelvis[NEOPLASMA MALIGNUM PELVIS RENIS,MUU/TARK MÄÄR SYÖPÄ]
+∞
11.6
11
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
11.6
11
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
12.2
11.3
20
18
WX402
NOMESCO Finland
General anaesthesia
3.6
11.3
43
141
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
19.1
10.9
16
9
KH1AD
NOMESCO Finland
CT of urinary organs
9.3
10.9
22
26
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.9
10.7
35
103
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
10.4
10.5
20
21
GD1AD
NOMESCO Finland
Thorax CT examination
5.2
10.5
23
49
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
115.6
10.5
11
*
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
+∞
10.5
10
*
R82.8
ICD-10 Finland
Abnormal findings on cytological and histological examination of urine
+∞
10.5
10
*
J01EA01
ATC
trimethoprim; systemic
2.9
10.3
62
266
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
17.8
10.0
15
9
J01MA02
ATC
ciprofloxacin; systemic
2.5
9.6
102
577
C67.0
ICD-10 Finland
Malignant neoplasm: Trigone of bladder
+∞
9.4
9
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
9.4
9
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
9.4
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.4
9
*
R50.9
ICD-10 Finland
Fever, unspecified
3.2
9.0
41
149
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.8
8.7
29
86
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
12.3
8.7
15
13
WW500
NOMESCO Finland
Blood transfusion
10.7
8.7
16
16
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.8
8.7
50
208
KCW96
NOMESCO Finland
Other operations on bladder
28.9
8.6
11
*
JN3AD
NOMESCO Finland
Abdominal CT examination
3.4
8.5
33
109
D41.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Ureter
+∞
8.4
8
*
WC305
NOMESCO Finland
Simple therapy of local tumor recidive with biomodifiers
+∞
8.4
8
*
U75
ICPC
Malignant neoplasm of kidney
+∞
8.4
8
*
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
23.1
8.1
11
5
WZC30
NOMESCO Finland
Teaching
3.2
7.8
34
120
KH1BD
NOMESCO Finland
Extensive urinary tract CT examination
46.8
7.8
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
7.8
57
267
L02AE02
ATC
leuprorelin; implant, parenteral
82.9
7.5
8
*
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
82.9
7.5
8
*
115
Kela drug reimbursment
Breast cancer
+∞
7.3
7
*
1530
FHL
Urethrocystoscopy
6.5
6.9
17
28
WX725
NOMESCO Finland
Noninvasive ventilation
4.2
6.9
19
49
ZXE20
NOMESCO Finland
More than three and less than five hours
2.8
6.8
38
155
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
23.4
6.7
9
*
K43.9
ICD-10 Finland
Other and unspecified ventral hernia without obstruction or gangrene
7.3
6.6
15
22
XKD00
NOMESCO Finland
Uroflowmetry
2.4
6.4
52
253
J01MA12
ATC
levofloxacin; systemic
2.4
6.4
52
253
KAB00
NOMESCO Finland
Biopsy of kidney or pelvis of kidney
+∞
6.3
6
*
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
+∞
6.3
6
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
6.3
6
*
C67
ICD-10 Finland
Malignant neoplasm of bladder
+∞
6.3
6
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
6.3
6
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
6.3
6
*
KA3GB
NOMESCO Finland
Retrograde pyelography
+∞
6.3
6
*
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
+∞
6.3
6
*
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
6.3
6
*
7321
FHL
TU biopsy, coagulation or laser
+∞
6.3
6
*
PJD43
NOMESCO Finland
Excision of aortic lymph nodes
+∞
6.3
6
*
KC1GD
NOMESCO Finland
CT cystography of bladder
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
A06AH03
ATC
naloxegol; oral
27.6
6.3
8
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.5
6.2
22
68
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
6.1
108
715
ZXE30
NOMESCO Finland
More than five and less than seven hours
5.3
6.0
17
34
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
125
557
4.12
22.54
6.6
3.0
—
—
—
0
0
117
591
3.24
15.63
3.6
2.3
—
—
—
0
0
32
68
5.38
14.80
2.2
1.3
73.94
2.63
ug/l
0.51
25
51
117
638
2.91
12.87
6.0
3.5
32.17
34.72
g/l
4.42
107
585
88
420
2.90
12.32
7.0
2.8
0.29
0.52
e6/l
0.98
77
318
71
303
3.04
12.15
2.9
2.1
—
—
—
0
0
54
203
3.24
11.41
8.2
5.8
104.30
104.44
mmol/l
0.07
54
203
117
681
2.64
10.70
8.2
5.1
1.19
1.21
mmol/l
0.91
109
601
124
743
2.66
10.68
9.0
5.5
1.20
1.21
mmol/l
0.71
101
630
51
202
3.02
9.74
7.0
6.0
13.41
10.96
kpa
2.11
46
195
51
202
3.02
9.74
7.0
6.0
5.23
5.08
kpa
0.56
46
194
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
49
4.90
9.55
3.2
2.5
0.38
0.36
u/ml
0.05
16
23
50
202
2.94
9.18
7.1
6.1
-0.80
1.32
mmol/l
1.93
34
157
128
827
2.42
8.70
20.1
18.7
1.37
1.47
inr
0.51
35
220
137
913
2.47
8.68
6.4
4.3
6.79
7.00
mmol/l
0.80
128
853
87
477
2.42
8.56
5.3
2.0
2.33
2.34
mmol/l
0.53
74
390
118
743
2.36
8.41
12.6
5.1
4.98
4.67
e9/l
0.43
105
638
53
245
2.56
7.40
6.6
2.6
2.33
1.14
e6/l
0.60
43
139
23
68
3.68
6.92
1.7
1.7
3.79
2.49
ug/l
0.23
18
54
29
115
2.77
5.40
4.1
3.5
95.32
87.72
ng/l
0.17
23
95
48
243
2.27
5.36
7.0
2.9
1.01
2.60
e6/l
1.54
37
137
51
271
2.17
5.04
1.8
1.6
30.10
29.38
s
0.36
51
259
25
102
2.65
4.41
1.8
1.5
—
—
—
0
0
99
701
1.79
4.07
6.2
4.0
0.00
0.00
estimate
-0.00
27
108
51
295
1.97
3.96
3.9
2.2
2.49
2.44
mmol/l
3.26
46
243
34
170
2.20
3.87
4.8
3.4
5.92
5.78
kpa
0.30
29
162
97
694
1.75
3.77
7.0
5.4
0.00
0.00
estimate
-0.00
26
113
13
34
4.01
3.76
2.1
2.1
1.83
1.84
mg/l
0.01
13
28
33
171
2.11
3.43
5.0
3.4
2.26
2.01
mmol/l
0.08
21
137
15
55
2.86
3.23
4.7
4.0
—
—
—
0
0
94
693
1.65
3.11
6.2
4.0
0.00
0.01
estimate
0.50
28
126
37
208
1.95
3.09
2.9
2.4
19.92
22.57
%
0.46
29
182
44
270
1.80
2.80
2.2
1.8
—
—
—
0
0
52
343
1.69
2.57
5.2
4.0
153.32
394.30
ng/l
0.79
44
296
33
192
1.85
2.49
2.2
1.8
—
—
—
0
0
21
104
2.13
2.46
3.0
2.0
38.92
57.80
ml/min/173m2
2.63
12
40
6
12
5.11
2.42
4.2
1.1
—
—
—
0
0
21
106
2.09
2.35
6.1
3.6
1.87
2.14
mmol/l
0.09
15
81
57
394
1.62
2.34
7.3
4.2
0.00
0.00
estimate
-0.00
19
109
12
48
2.59
2.23
2.2
1.3
—
1.33
—
0
7
8
24
3.42
2.20
1.3
1.3
—
—
—
0
0
32
194
1.77
2.12
2.3
1.8
—
—
—
0
0
60
431
1.55
2.07
2.0
2.1
2.67
3.16
mg/l
0.98
52
349
74
557
1.51
2.06
6.9
4.2
—
—
—
0
0
6
15
4.09
2.05
4.7
5.9
14.60
12.19
mg/l
—
6
15
11
44
2.58
2.04
1.2
1.3
—
—
—
0
0
54
389
1.52
1.83
3.3
2.6
9154.67
12421.41
umol/l
0.13
46
328
98
799
1.43
1.76
3.3
3.1
66.63
54.92
u/l
0.41
92
727
158
1408
1.51
1.75
29.3
14.8
44.52
26.41
mg/l
6.61
151
1100
67
512
1.46
1.69
2.2
2.2
112.90
256.37
u/l
2.08
61
470
96
785
1.41
1.67
4.3
4.1
2.17
2.23
ug/l
0.08
73
684
6
19
3.22
1.67
1.3
1.3
—
—
—
0
0
122
1045
1.41
1.60
4.9
4.1
21.42
13.50
mm/h
3.13
106
926
6
20
3.06
1.59
1.0
1.2
0.75
0.59
nmol/l
—
6
15
6
21
2.91
1.51
1.2
1.2
—
—
—
0
0
20
117
1.78
1.51
3.7
2.1
37.95
33.65
u/l
0.29
20
93
9
38
2.43
1.47
1.1
1.5
—
—
—
0
0
7
29
2.46
1.40
1.3
2.1
74.86
84.62
%
—
7
29
6
23
2.65
1.37
4.0
1.6
—
—
—
0
0
5
17
2.99
1.36
1.4
1.4
—
—
—
0
0
5
18
2.82
1.29
1.2
1.5
—
—
—
0
0
5
18
2.82
1.29
1.2
1.5
—
—
—
0
0
25
164
1.60
1.27
5.3
3.3
—
—
—
0
0
6
25
2.44
1.25
1.3
2.7
62.83
62.84
%
—
6
25
22
144
1.59
1.14
3.8
2.8
4.19
4.39
kpa
0.17
17
134
69
568
1.32
1.07
3.6
3.9
16.41
9.95
mg/mmol
0.97
47
355
7
33
2.16
1.06
1.1
1.5
—
—
—
0
0
7
34
2.09
1.04
1.1
1.5
—
—
—
0
0
7
34
2.09
1.04
1.1
1.2
—
—
—
0
0
84
717
1.29
0.99
4.0
4.4
48.35
97.01
ng/l
0.52
72
560
16
101
1.63
0.97
1.2
1.5
—
—
—
0
0
7
37
1.92
0.95
1.3
1.4
—
—
—
0
0
38
294
1.36
0.88
1.6
1.6
1.54
1.35
mg/l
0.23
32
227
15
96
1.61
0.87
2.6
1.6
—
—
—
0
0
9
54
1.70
0.75
1.9
1.9
—
132.00
—
0
5
21
151
1.43
0.75
3.3
2.0
9.57
7.11
umol/l
0.29
21
129
5
26
1.95
0.71
1.0
1.5
—
—
—
0
0
48
398
1.27
0.70
1.6
1.8
403.30
396.35
pmol/l
0.07
33
312
5
27
1.87
0.69
1.0
1.2
—
—
—
0
0
66
570
1.23
0.67
3.3
2.6
252.53
144.60
ug/l
1.66
59
504
112
1023
1.21
0.65
4.2
3.4
15.36
15.18
pmol/l
0.33
97
890
157
1485
1.23
0.61
40.2
17.6
116.77
86.88
umol/l
11.44
157
1485
10
64
1.59
0.59
2.5
1.6
—
—
—
0
0
6
35
1.73
0.58
1.5
1.5
—
—
—
0
0
71
627
1.20
0.58
3.1
3.3
3850.56
2000.63
ng/l
1.48
66
546
9
59
1.55
0.55
2.7
1.5
—
—
—
0
0
156
1484
1.20
0.52
15.6
9.0
21.88
25.11
u/l
2.00
150
1402
128
1357
0.85
0.49
7.8
6.8
41.13
41.72
mmol/mol
0.32
113
1236
30
361
0.80
0.48
1.8
1.7
1.31
1.34
mmol/l
0.06
24
283
47
407
1.20
0.47
1.9
1.8
1122.83
1200.51
nmol/l
0.17
35
308
79
718
1.16
0.45
2.2
2.1
93.25
92.16
pmol/l
0.10
45
361
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.5
—
—
—
0
0
124
1306
0.87
0.39
4.2
4.4
1.24
1.25
mmol/l
0.05
109
1147
68
621
1.14
0.36
4.4
3.9
22.81
24.51
%
0.48
34
304
62
565
1.14
0.33
1.9
2.3
72.93
78.53
nmol/l
0.85
51
473
135
1407
0.88
0.33
5.6
5.0
6.05
6.17
mmol/l
0.66
117
1227
159
1537
1.15
0.32
43.8
21.5
36.25
39.67
%
6.87
144
1391
131
1366
0.89
0.32
4.8
4.9
4.15
4.32
mmol/l
1.02
116
1232
16
196
0.80
0.31
1.3
1.3
14.71
43.15
iu/ml
—
7
67
136
1414
0.89
0.31
5.1
5.5
2.31
2.49
mmol/l
1.60
117
1259
25
213
1.20
0.31
14.1
8.1
—
—
—
0
0
7
57
1.24
0.29
1.0
1.2
11.07
10.73
g/l
—
7
48
130
1351
0.90
0.28
4.7
4.9
1.32
1.41
mmol/l
1.30
117
1199
8
67
1.20
0.26
1.0
1.3
—
—
—
0
0
8
67
1.20
0.26
1.0
1.3
4.76
3.73
g/l
—
8
58
8
67
1.20
0.26
1.0
1.3
9.48
7.55
g/l
—
8
58
46
420
1.12
0.24
3.3
2.7
0.82
0.78
ug/l
0.13
27
293
158
1538
1.11
0.24
44.6
21.4
4.11
4.46
e12/l
12.68
153
1459
5
39
1.29
0.23
1.2
1.4
—
—
—
0
0
12
98
1.24
0.21
1.7
2.1
10.71
14.85
nmol/l
0.96
12
87
0
11
0.00
0.21
0.0
1.1
—
157.31
—
0
11
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
6
51
1.18
0.19
1.0
1.2
36.75
37.36
g/l
—
6
42
134
1304
1.08
0.17
31.3
13.7
54.82
71.76
ml/min/173m2
17.22
120
1041
46
430
1.09
0.16
1.6
1.6
15.56
19.94
nmol/l
1.53
40
354
7
64
1.10
0.08
1.0
1.3
3.84
3.00
g/l
—
7
55
19
201
0.94
0.04
4.3
4.9
33.89
33.17
%
—
9
132
63
617
1.03
0.04
2.6
2.2
—
—
—
0
0
130
1296
1.01
0.00
5.5
4.3
1.85
2.03
mu/l
1.07
118
1123
11
108
1.02
0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
61.40
—
0
8
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
156.38
—
0
8
0
8
0.00
0.00
0.0
1.3
—
63.50
—
0
8
0
6
0.00
-0.00
0.0
1.3
—
1.27
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
205.56
—
0
9
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
7
79
0.88
-0.00
1.1
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
15.12
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
10.43
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_RENAL_PELVIS – Malignant neoplasm of renal pelvis
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).